Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 19 entries
Sorted by: Best Match Show Resources per page
[Not Available].

Therapie

Bentué-Ferrer D, Tribut O, Verdier MC.
PMID: 27392919
Therapie. 2010 Jan-Feb;65(1):23-7. doi: 10.2515/therapie/2009067.

Vigabatrin is a second generation anticonvulsant drug available in France since 1995. It is an amino acid analogue of the GABA, marketed under the racemic form [R(-)/S(+)50/50], but only the S(+)-enantiomer is active. Neither the mechanism of action of...

Cite
Bentué-Ferrer D, Tribut O, Verdier MC. Suivi thérapeutique pharmacologique du vigabatrin. [Not Available]. Therapie. 2010;65(1):23-7doi: 10.2515/therapie/2009067.
Bentué-Ferrer, D., Tribut, O., Verdier, M. C. (2010). Suivi thérapeutique pharmacologique du vigabatrin. [Not Available]. Therapie, 65(1), 23-7. https://doi.org/10.2515/therapie/2009067
Bentué-Ferrer, Danièle, et al. "Suivi thérapeutique pharmacologique du vigabatrin." [Not Available]. Therapie vol. 65,1 (2010): 23-7. doi: https://doi.org/10.2515/therapie/2009067
Bentué-Ferrer D, Tribut O, Verdier MC. Suivi thérapeutique pharmacologique du vigabatrin. [Not Available]. Therapie. 2010 Jan-Feb;65(1):23-7. doi: 10.2515/therapie/2009067. French. PMID: 27392919.
Copy Download .nbib Format: NLM
[Not Available].

Therapie

Bentué-Ferrer D, Tribut O, Verdier MC.
PMID: 27392924
Therapie. 2010 Jan-Feb;65(1):51-5. doi: 10.2515/therapie/2009065.

Tiagabine, a second-generation anticonvulsant drug, is marketed in France since 1997. It is also prescribed outside marketing authorization in the treatment of anxiety. They are few studies allowing arguing a relation exposure efficiency or toxicity, but intra and inter...

Cite
Bentué-Ferrer D, Tribut O, Verdier MC. Suivi thérapeutique pharmacologique de la tiagabine. [Not Available]. Therapie. 2010;65(1):51-5doi: 10.2515/therapie/2009065.
Bentué-Ferrer, D., Tribut, O., Verdier, M. C. (2010). Suivi thérapeutique pharmacologique de la tiagabine. [Not Available]. Therapie, 65(1), 51-5. https://doi.org/10.2515/therapie/2009065
Bentué-Ferrer, Danièle, et al. "Suivi thérapeutique pharmacologique de la tiagabine." [Not Available]. Therapie vol. 65,1 (2010): 51-5. doi: https://doi.org/10.2515/therapie/2009065
Bentué-Ferrer D, Tribut O, Verdier MC. Suivi thérapeutique pharmacologique de la tiagabine. [Not Available]. Therapie. 2010 Jan-Feb;65(1):51-5. doi: 10.2515/therapie/2009065. French. PMID: 27392924.
Copy Download .nbib Format: NLM
[Not Available].

Therapie

Chevreuil C, Polard E, Lemonnier E, Guillemot P, Bentué-Ferrer D.
PMID: 27393647
Therapie. 2011 Mar-Apr;66(2):123-30. doi: 10.2515/therapie/2011012.

Aripiprazole inaugurates a new generation of antipsychotics called dopamine-serotonin system stabilizers. Its mechanism of action is different as aripiprazole is a partial dopamine D2 and serotonin 5-HT1A receptor agonist and 5-HT2A receptor antagonist. Therefore, aripiprazole is thought to have...

Cite
Chevreuil C, Polard E, Lemonnier E, et al. Prescription de l'aripiprazole chez l'enfant et l'adolescent. [Not Available]. Therapie. 2011;66(2):123-30doi: 10.2515/therapie/2011012.
Chevreuil, C., Polard, E., Lemonnier, E., Guillemot, P., & Bentué-Ferrer, D. (2011). Prescription de l'aripiprazole chez l'enfant et l'adolescent. [Not Available]. Therapie, 66(2), 123-30. https://doi.org/10.2515/therapie/2011012
Chevreuil, Claire, et al. "Prescription de l'aripiprazole chez l'enfant et l'adolescent." [Not Available]. Therapie vol. 66,2 (2011): 123-30. doi: https://doi.org/10.2515/therapie/2011012
Chevreuil C, Polard E, Lemonnier E, Guillemot P, Bentué-Ferrer D. Prescription de l'aripiprazole chez l'enfant et l'adolescent. [Not Available]. Therapie. 2011 Mar-Apr;66(2):123-30. doi: 10.2515/therapie/2011012. French. PMID: 27393647.
Copy Download .nbib Format: NLM
Suivi thérapeutique pharmacologique de la prégabaline.

Therapie

Bentué-Ferrer D, Tribut O, Verdier MC.
PMID: 27392923
Therapie. 2010 Jan-Feb;65(1):47-50. doi: 10.2515/therapie/2009064.

Pregabaline, a second generation antiepileptic, is marketed in France since 2005. It is also indicated in the treatment of painful neuropathy and in generalized anxious disorder. Its pharmacokinetic profile: low metabolism and no binding to plasma proteins, is not...

Cite
Bentué-Ferrer D, Tribut O, Verdier MC. Suivi thérapeutique pharmacologique de la prégabaline. Therapie. 2010;65(1):47-50doi: 10.2515/therapie/2009064.
Bentué-Ferrer, D., Tribut, O., Verdier, M. C. (2010). Suivi thérapeutique pharmacologique de la prégabaline. Therapie, 65(1), 47-50. https://doi.org/10.2515/therapie/2009064
Bentué-Ferrer, Danièle, et al. "Suivi thérapeutique pharmacologique de la prégabaline." Therapie vol. 65,1 (2010): 47-50. doi: https://doi.org/10.2515/therapie/2009064
Bentué-Ferrer D, Tribut O, Verdier MC. Suivi thérapeutique pharmacologique de la prégabaline. Therapie. 2010 Jan-Feb;65(1):47-50. doi: 10.2515/therapie/2009064. PMID: 27392923.
Copy Download .nbib Format: NLM
[Not Available].

Therapie

Debruyne D, Pailliet-Loilier M, Lelong-Boulouard V, Coquerel A, Bentué-Ferrer D.
PMID: 27392990
Therapie. 2010 May-Jun;65(3):219-24. doi: 10.2515/therapie/2010027.

Clonazepam is a 1-4 benzodiazepine mainly used to treat epilepsy and epileptiform convulsion state. Rapidly absorbed after oral administration, it is widely distributed in the organism and is extensively converted in metabolites, poorly or not active, eliminated mainly in...

Cite
Debruyne D, Pailliet-Loilier M, Lelong-Boulouard V, et al. Suivi thérapeutique pharmacologique du clonazépam. [Not Available]. Therapie. 2010;65(3):219-24doi: 10.2515/therapie/2010027.
Debruyne, D., Pailliet-Loilier, M., Lelong-Boulouard, V., Coquerel, A., Bentué-Ferrer, D. (2010). Suivi thérapeutique pharmacologique du clonazépam. [Not Available]. Therapie, 65(3), 219-24. https://doi.org/10.2515/therapie/2010027
Debruyne, Danièle, et al. "Suivi thérapeutique pharmacologique du clonazépam." [Not Available]. Therapie vol. 65,3 (2010): 219-24. doi: https://doi.org/10.2515/therapie/2010027
Debruyne D, Pailliet-Loilier M, Lelong-Boulouard V, Coquerel A, Bentué-Ferrer D. Suivi thérapeutique pharmacologique du clonazépam. [Not Available]. Therapie. 2010 May-Jun;65(3):219-24. doi: 10.2515/therapie/2010027. French. PMID: 27392990.
Copy Download .nbib Format: NLM
[Therapeutic drug monitoring of olanzapine].

Therapie

Djerada Z, Brousse G, Niel P, Llorca PM, Eschalier A, Bentue-Ferrer D, Libert F.
PMID: 27793422
Therapie. 2016 Oct 25; doi: 10.2515/therapie/2015040. Epub 2016 Oct 25.

Olanzapine, atypical antipsychotic, is used to treat schizophrenia and bipolar disorder. Its therapeutic drug monitoring (TDM) is quite commonly done. Olanzapine is well absorbed orally (bioavailability: 85 %), with peak plasma occurring between 4 and 6hours after oral administration....

Cite
Djerada Z, Brousse G, Niel P, et al. Suivi thérapeutique pharmacologique de l’olanzapine. [Therapeutic drug monitoring of olanzapine]. Therapie. 2016;doi: 10.2515/therapie/2015040.
Djerada, Z., Brousse, G., Niel, P., Llorca, P. M., Eschalier, A., Bentue-Ferrer, D., Libert, F. (2016). Suivi thérapeutique pharmacologique de l’olanzapine. [Therapeutic drug monitoring of olanzapine]. Therapie, . https://doi.org/10.2515/therapie/2015040
Djerada, Zoubir, et al. "Suivi thérapeutique pharmacologique de l’olanzapine." [Therapeutic drug monitoring of olanzapine]. Therapie vol. (2016). doi: https://doi.org/10.2515/therapie/2015040
Djerada Z, Brousse G, Niel P, Llorca PM, Eschalier A, Bentue-Ferrer D, Libert F. Suivi thérapeutique pharmacologique de l’olanzapine. [Therapeutic drug monitoring of olanzapine]. Therapie. 2016 Oct 25; doi: 10.2515/therapie/2015040. Epub 2016 Oct 25. French. PMID: 27793422.
Copy Download .nbib Format: NLM
[Not Available].

Therapie

Bentué-Ferrer D, Tribut O, Verdier MC.
PMID: 27392918
Therapie. 2010 Jan-Feb;65(1):17-22. doi: 10.2515/therapie/2009066.

Topiramate, a second generation anticonvulsant drug, is marketed in France since 1997. It is also indicated in the prophylaxis of headache and is used, except legal notices, in the treatment of neuropathic pains and bipolar disorders. The efficiency and...

Cite
Bentué-Ferrer D, Tribut O, Verdier MC. Suivi thérapeutique pharmacologique du topiramate. [Not Available]. Therapie. 2010;65(1):17-22doi: 10.2515/therapie/2009066.
Bentué-Ferrer, D., Tribut, O., Verdier, M. C. (2010). Suivi thérapeutique pharmacologique du topiramate. [Not Available]. Therapie, 65(1), 17-22. https://doi.org/10.2515/therapie/2009066
Bentué-Ferrer, Danièle, et al. "Suivi thérapeutique pharmacologique du topiramate." [Not Available]. Therapie vol. 65,1 (2010): 17-22. doi: https://doi.org/10.2515/therapie/2009066
Bentué-Ferrer D, Tribut O, Verdier MC. Suivi thérapeutique pharmacologique du topiramate. [Not Available]. Therapie. 2010 Jan-Feb;65(1):17-22. doi: 10.2515/therapie/2009066. French. PMID: 27392918.
Copy Download .nbib Format: NLM
Suivi thérapeutique pharmacologique de la lamotrigine.

Therapie

Bentué-Ferrer D, Tribut O, Verdier MC.
PMID: 27392922
Therapie. 2010 Jan-Feb;65(1):39-46. doi: 10.2515/therapie/2009063.

Lamotrigine is a second generation anticonvulsant drug available in France since 1996. As other anticonvulsant drugs, lamotrigine is also used in type I bipolar disorders and except legal notices, in the treatment of neuropathic pains. It is mainly metabolized...

Cite
Bentué-Ferrer D, Tribut O, Verdier MC. Suivi thérapeutique pharmacologique de la lamotrigine. Therapie. 2010;65(1):39-46doi: 10.2515/therapie/2009063.
Bentué-Ferrer, D., Tribut, O., Verdier, M. C. (2010). Suivi thérapeutique pharmacologique de la lamotrigine. Therapie, 65(1), 39-46. https://doi.org/10.2515/therapie/2009063
Bentué-Ferrer, Danièle, et al. "Suivi thérapeutique pharmacologique de la lamotrigine." Therapie vol. 65,1 (2010): 39-46. doi: https://doi.org/10.2515/therapie/2009063
Bentué-Ferrer D, Tribut O, Verdier MC. Suivi thérapeutique pharmacologique de la lamotrigine. Therapie. 2010 Jan-Feb;65(1):39-46. doi: 10.2515/therapie/2009063. PMID: 27392922.
Copy Download .nbib Format: NLM
The anti-dementia drugs: myth, hype or reality?.

Clinical neuropharmacology

Allain H, Hervé A, Bentué-Ferrer D.
PMID: 16518127
Clin Neuropharmacol. 2006 Jan-Feb;29(1):10-4. doi: 10.1097/00002826-200601000-00004.

The neurodegenerative diseases are in need of drugs that are capable of treating their many different presentations. Some drugs have recently been developed and approved by the authorities for use in Alzheimer's disease; their beneficial effects are no longer...

Cite
Allain H, Hervé A, Bentué-Ferrer D. The anti-dementia drugs: myth, hype or reality?. Clin Neuropharmacol. 2006;29(1):10-4doi: 10.1097/00002826-200601000-00004.
Allain, H., Hervé, A., & Bentué-Ferrer, D. (2006). The anti-dementia drugs: myth, hype or reality?. Clinical neuropharmacology, 29(1), 10-4. https://doi.org/10.1097/00002826-200601000-00004
Allain, Hervé, et al. "The anti-dementia drugs: myth, hype or reality?." Clinical neuropharmacology vol. 29,1 (2006): 10-4. doi: https://doi.org/10.1097/00002826-200601000-00004
Allain H, Hervé A, Bentué-Ferrer D. The anti-dementia drugs: myth, hype or reality?. Clin Neuropharmacol. 2006 Jan-Feb;29(1):10-4. doi: 10.1097/00002826-200601000-00004. PMID: 16518127.
Copy Download .nbib Format: NLM
Impaired cognition and attention in adults: pharmacological management strategies.

Neuropsychiatric disease and treatment

Allain H, Akwa Y, Lacomblez L, Lieury A, Bentué-Ferrer D.
PMID: 19300541
Neuropsychiatr Dis Treat. 2007 Feb;3(1):103-16. doi: 10.2147/nedt.2007.3.1.103.

Cognitive psychology has provided clinicians with specific tools for analyzing the processes of cognition (memory, language) and executive functions (attention-concentration, abstract reasoning, planning). Neuropsychology, coupled with the neurosciences (including neuroimaging techniques), has authenticated the existence of early disorders affecting...

Cite
Allain H, Akwa Y, Lacomblez L, et al. Impaired cognition and attention in adults: pharmacological management strategies. Neuropsychiatr Dis Treat. 2007;3(1):103-16doi: 10.2147/nedt.2007.3.1.103.
Allain, H., Akwa, Y., Lacomblez, L., Lieury, A., & Bentué-Ferrer, D. (2007). Impaired cognition and attention in adults: pharmacological management strategies. Neuropsychiatric disease and treatment, 3(1), 103-16. https://doi.org/10.2147/nedt.2007.3.1.103
Allain, Hervé, et al. "Impaired cognition and attention in adults: pharmacological management strategies." Neuropsychiatric disease and treatment vol. 3,1 (2007): 103-16. doi: https://doi.org/10.2147/nedt.2007.3.1.103
Allain H, Akwa Y, Lacomblez L, Lieury A, Bentué-Ferrer D. Impaired cognition and attention in adults: pharmacological management strategies. Neuropsychiatr Dis Treat. 2007 Feb;3(1):103-16. doi: 10.2147/nedt.2007.3.1.103. PMID: 19300541; PMCID: PMC2654526.
Copy Download .nbib Format: NLM
[Not Available].

Therapie

Bouquié R, Dailly E, Bentué-Ferrer D.
PMID: 27392926
Therapie. 2010 Jan-Feb;65(1):61-5. doi: 10.2515/therapie/2009070.

Oxcarbazepine is an analogue of carbamazepine, used for the treatment of partial seizure with or without secondary generalization. The two forms R and S of the mono-hydroxylated derivatives (MHD) are responsible for most of the anti-convulsant activity and it...

Cite
Bouquié R, Dailly E, Bentué-Ferrer D. Suivi thérapeutique pharmacologique de l'oxcarbazépine. [Not Available]. Therapie. 2010;65(1):61-5doi: 10.2515/therapie/2009070.
Bouquié, R., Dailly, E., Bentué-Ferrer, D. (2010). Suivi thérapeutique pharmacologique de l'oxcarbazépine. [Not Available]. Therapie, 65(1), 61-5. https://doi.org/10.2515/therapie/2009070
Bouquié, Régis, et al. "Suivi thérapeutique pharmacologique de l'oxcarbazépine." [Not Available]. Therapie vol. 65,1 (2010): 61-5. doi: https://doi.org/10.2515/therapie/2009070
Bouquié R, Dailly E, Bentué-Ferrer D. Suivi thérapeutique pharmacologique de l'oxcarbazépine. [Not Available]. Therapie. 2010 Jan-Feb;65(1):61-5. doi: 10.2515/therapie/2009070. French. PMID: 27392926.
Copy Download .nbib Format: NLM
[Therapeutic drug monitoring of clozapine].

Therapie

Djerada Z, Daviet F, Llorca PM, Eschalier A, Saint-Marcoux F, Bentué-Ferrer D, Libert F.
PMID: 27771104
Therapie. 2016 Aug 24; doi: 10.2515/therapie/2015041. Epub 2016 Aug 24.

Clozapine is a prototypical atypical antipsychotic used to treat severe schizophrenia and for which a therapeutic drug monitoring (TDM) is quite commonly proposed. Clozapine is rapidly absorbed (maximum concentration reached within 1 to 4hours), and is extensively metabolized in...

Cite
Djerada Z, Daviet F, Llorca PM, et al. Suivi thérapeutique pharmacologique de la clozapine. [Therapeutic drug monitoring of clozapine]. Therapie. 2016;doi: 10.2515/therapie/2015041.
Djerada, Z., Daviet, F., Llorca, P. M., Eschalier, A., Saint-Marcoux, F., Bentué-Ferrer, D., Libert, F. (2016). Suivi thérapeutique pharmacologique de la clozapine. [Therapeutic drug monitoring of clozapine]. Therapie, . https://doi.org/10.2515/therapie/2015041
Djerada, Zoubir, et al. "Suivi thérapeutique pharmacologique de la clozapine." [Therapeutic drug monitoring of clozapine]. Therapie vol. (2016). doi: https://doi.org/10.2515/therapie/2015041
Djerada Z, Daviet F, Llorca PM, Eschalier A, Saint-Marcoux F, Bentué-Ferrer D, Libert F. Suivi thérapeutique pharmacologique de la clozapine. [Therapeutic drug monitoring of clozapine]. Therapie. 2016 Aug 24; doi: 10.2515/therapie/2015041. Epub 2016 Aug 24. French. PMID: 27771104.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 19 entries